Behind Options MD is a team of experienced medical experts. They worked together with the founders, Morgan and Kyle, to create a unique virtual healthcare practice focused on providing treatment to individuals with major depressive disorder who have treatment-resistant depression.
The medical experts behind Options MD bring together a wealth of experience and knowledge in the healthcare industry. Each of their unique experiences helped to shape the individual care treatment and approach that makes Options MD different.
Dr. Marci is a physician, scientist, author, and entrepreneur in the health and technology sectors. He is a board-certified psychiatrist at Massachusetts General Hospital and a part-time Assistant Professor of Psychiatry at Harvard Medical School.
Dr. Marci is a strategic advisor and Interim Chief Medical Officer to Options MD. He has worked hand-in-hand with Options MD’s founders on go-to-market and clinical operations strategies.
He has been integral in developing Options MD’s patient assessment and treatment-matching logic, as well as helping management recruiting and onboard clinical hires.
Previously, Dr. Marci was Chief Psychiatrist or Chief Medical Officer at a number of venture-backed technology-enabled companies. He was the co-founder, Chairman, and Chief Executive Officer of Innerscope Research, a pioneer in the field of consumer neuroscience. Innerscope Research was a data science and media research firm acquired by Nielsen in 2015, where he served as the first Global Chief Neuroscientist until 2019.
Dr. Marci received his B.A. with honors from Columbia University, M.A. from Oxford University as a Rhodes Scholar, and M.D. with honors from Harvard Medical School.
He completed two NIH fellowships in neuroscience, published numerous articles in peer-reviewed science journals, holds seven patents, and gives lectures nationally and internationally.
He is also the author of a new book on the impact of mobile media, communications, and information technology on the developing brain, published by Harvard University Press. The book is titled “Rewired: Protecting Your Brain in the Digital Age.”
Dr. Marci is also a member of the Aspen Global Leadership Network as a 2014 Henry Crown Fellow.
Dr. Vaidya is a board-certified adult psychiatrist with fellowship training in Psychosomatic Medicine. She currently serves as the Lead Psychiatrist at Options MD and treats patients in New York.
She has practiced as a psychiatrist for more than 20 years. She is passionate about women’s health, collaborative care psychiatry and using cutting-edge health technologies to help patients with treatment resistant mental health conditions.
In her career as a psychiatrist, Dr. Vaidya has served as the Fellowship Director for Consult Liaison Psychiatry at the Icahn School of Medicine (ICSOM) as well as the Director of Transplant Psychiatry at ICSOM. She has also previously held positions as the Clinical Operations Chief at Kaiser Permanente in WA and a Physician Executive at MultiCare Behavioral health hospital. Prior to joining Options MD, she served as a Collaborative Care Psychiatrist at Crossover, providing care to Microsoft employees.
In addition to treating patients at Options MD, she currently serves as an Advisory Board Member for Gennev, a leading telehealth company dedicated to providing specialized care for menopausal women and a Physician Ambassador for Solve Care.
Andrew Leuchter, MD, is an expert on the treatment of mood disorders and is a Medical Advisor to Options MD. He is a Distinguished Professor of Psychiatry and Behavioral Sciences at UCLA, where he also directs the Neuromodulation Division as well as the Transcranial Magnetic Stimulation (TMS) Clinical and Research Service. The TMS Clinical and Research Service perform more than 7,000 individual TMS treatments each year for patients with treatment-resistant depression, chronic pain, obsessive-compulsive disorder, and other neuropsychiatric illnesses.
He also maintains an active clinical practice, specializing in consultation and care for patients suffering from treatment-resistant depression.
Dr. Leuchter leads clinical trials to develop novel neuromodulation methods for the treatment of depression, pain, and Post-Traumatic Stress Disorder (PTSD), studying technologies such as TMS and Trigeminal Nerve Stimulation (TNS). He uses brain-imaging techniques, such as quantitative electroencephalography (qEEG), magnetic resonance imaging (MRI), and positron emission tomography (PET), to examine brain function and predict which treatments are most likely to benefit individual patients.
Dr. Leuchter’s research programs combine clinical trials with neurophysiology and brain-imaging studies to inform clinical practice in treating depression.
He has authored over 200 scientific articles on topics including theories of antidepressant action, neuromodulation for the treatment of depression, and EEG biomarkers to guide the treatment of neuropsychiatric illness.
Dr.Leuchter is a member of several professional organizations, including the American Psychiatric Association and the Clinical TMS Society.
He is a graduate of Stanford University earned his medical degree at the Baylor College of Medicine in Houston, Texas.
Dr. Cohen is an adult psychiatrist, serves as Head of Data Science at Options MD, and is a part-time Volunteer Clinical Professor at the University of California San Francisco. He has extensive experience with treatment-resistant depression, as well as conducting research on new treatment strategies.
As Option MD's Head of Data Science, Dr. Cohen is developing patient assessment tools to more accurately diagnose patients, predict side effects, identify personalized treatment plans for patients, and track symptoms and recovery over time.
Before joining Options MD, Dr. Cohen was on faculty at the University of California San Francisco where he saw patients in their Specialty Depression and Transcranial Magnetic Stimulation Clinics. He also conducted clinical trials testing novel neuromodulation technologies for the treatment of depression.
Dr. Cohen completed his General Psychiatry Residency Training at the University of California San Francisco and served as Chief Resident for Research.
Dr. Cohen has a great deal of experience using a wide variety of psychopharmacological, behavioral, and interventional approaches, including the most cutting-edge treatments for depression, such as Transcranial Magnetic Stimulation and Ketamine. At Options MD, his approach to care is collaborative and he aims to be a partner on your journey to relief and mental well-being. He works with patients to help identify root causes of mental distress and provide treatment that addresses these root causes directly
Mon-Fri 9am - 5pm EST (6am - 2pm PST)
The 988 Suicide and Crisis Lifeline: 988 | Crisis Text Line: Text HOME to 741741
